INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Bizily Scott sold FDMT

Chief Legal Officer · 4D Molecular Therapeutics, Inc. · Common Stock

Side
SELL
Value
$118K
Shares
9,810
Price
$12
Executed
Jun 23, 2026
Disclosed
Jun 25, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jun 23 executedJun 25, 2026 disclosed

FDMT · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
25/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+16 / 25

    $118K reported value · 53.2% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · FDMT

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    11
    BS
    Bizily ScottChief Legal Officer
    FDMT4D Molecular Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$41K
    9,810 sh
    		Jun 23, 2026Jun 25, 2026
    traded Jun 23, 2026
    		+2dSEC FORM 4

    Evidence

    3
    BS
    Bizily ScottChief Legal Officer
    FDMT4D Molecular Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    9,810 sh
    		Jun 23, 2026Jun 25, 2026
    traded Jun 23, 2026
    		+2dSEC FORM 4

    Evidence

    23
    KD
    Kirn DavidDirector, See Remarks
    FDMT4D Molecular Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.20M
    114.7K sh
    		Jun 22, 2026Jun 23, 2026
    traded Jun 22, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001920738-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 23, 2026
    Published
    Jun 25, 2026
    Ingested by INSIDER
    Nov 5, 03:51 UTC
    Last re-read
    Nov 5, 03:51 UTC

    Extracted facts

    Filer
    Bizily Scott
    Role
    Chief Legal Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    4D Molecular Therapeutics, Inc.
    Ticker
    FDMT
    Shares
    9,810
    Price per share
    $12
    Value
    $117,720
    Execution date (reported)
    Jun 23, 2026
    Owned after transaction
    8,617 shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 9,810
    • Price: $12

    = $117,720

    What this establishes

    Bizily Scott filed this Form 4 reporting a open-market sale of FDMT on Jun 23, 2026. It became public on Jun 25, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Legal Officer
    Bizily Scottcik:0001920738
    Issuer
    4D Molecular Therapeutics, Inc.cik:0001650648

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.